Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Lexicon Pharmaceuticals, Inc. - Common Stock
(NQ:
LXRX
)
2.550
+0.260 (+11.35%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 26, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Lexicon Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
Lexicon Announces Receipt of Complete Response Letter for Zynquista™ (sotagliflozin)
December 20, 2024
Confirms Previously Disclosed and Anticipated FDA Decision
From
Lexicon Pharmaceuticals, Inc.
Via
GlobeNewswire
2 Generic Drug Stocks Ready to Surge in 2025
November 27, 2024
Explore how Teva Pharmaceuticals and Viatris are leading the generics industry with strong growth, robust pipelines, and strategies for 2025 success.
Via
MarketBeat
Topics
Government
Intellectual Property
Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)
November 26, 2024
From
Lexicon Pharmaceuticals, Inc.
Via
GlobeNewswire
Demystifying Lexicon Pharmaceuticals: Insights From 10 Analyst Reviews
↗
November 13, 2024
Via
Benzinga
Earnings Scheduled For November 12, 2024
↗
November 12, 2024
Via
Benzinga
Preview: Lexicon Pharmaceuticals's Earnings
↗
November 11, 2024
Via
Benzinga
The Analyst Landscape: 11 Takes On Lexicon Pharmaceuticals
↗
November 05, 2024
Via
Benzinga
Lexicon Pharmaceuticals to Participate in December Investor Conferences
November 25, 2024
From
Lexicon Pharmaceuticals, Inc.
Via
GlobeNewswire
Lexicon to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA
November 22, 2024
From
Lexicon Pharmaceuticals, Inc.
Via
GlobeNewswire
Lexicon Appoints Ivan H. Cheung to Board of Directors
November 20, 2024
From
Lexicon Pharmaceuticals, Inc.
Via
GlobeNewswire
What You Missed On Wall Street This Past Friday
↗
November 03, 2024
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.
Via
Talk Markets
Beyond The Numbers: 7 Analysts Discuss Lexicon Pharmaceuticals Stock
↗
September 27, 2024
Via
Benzinga
The Analyst Verdict: Lexicon Pharmaceuticals In The Eyes Of 8 Experts
↗
September 03, 2024
Via
Benzinga
Crude Oil Moves Higher; Apple Shares Slide After Q4 Results
↗
November 01, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
↗
November 01, 2024
Via
Benzinga
Nasdaq Surges Over 200 Points; Amazon Shares Jump After Strong Results
↗
November 01, 2024
Via
Benzinga
Dow Jumps 400 Points; US Adds 12,000 Jobs In October
↗
November 01, 2024
Via
Benzinga
Topics
Stocks
Why Charter Communications Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket
↗
November 01, 2024
Via
Benzinga
Analyst Scoreboard: 6 Ratings For Lexicon Pharmaceuticals
↗
August 13, 2024
Via
Benzinga
FDA Panel Rejects Lexicon's Zynquista For Type 1 Diabetes
↗
November 01, 2024
Lexicon Pharmaceuticals' sotagliflozin, under review as an adjunct to insulin for type 1 diabetes and CKD, faced an FDA panel vote against approval, with mixed expert support.
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
↗
November 01, 2024
Via
Benzinga
Deep Dive Into Lexicon Pharmaceuticals Stock: Analyst Perspectives (9 Ratings)
↗
October 23, 2024
Via
Benzinga
Peeling Back The Layers: Exploring Lexicon Pharmaceuticals Through Analyst Insights
↗
October 17, 2024
Via
Benzinga
5 Analysts Have This To Say About Lexicon Pharmaceuticals
↗
August 02, 2024
Via
Benzinga
Why DoorDash Shares Are Trading Higher By 10%; Here Are 20 Stocks Moving Premarket
↗
August 02, 2024
Via
Benzinga
Intel Reports Weak Results, Joins Amazon, Opendoor Technologies And Other Big Stocks Moving Lower In Friday's Pre-Market Session
↗
August 02, 2024
Via
Benzinga
Why Ovid Therapeutics Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session
↗
June 17, 2024
Via
Benzinga
Aaron's, Nvidia, Mirum Pharmaceuticals, Primo Water And Other Big Stocks Moving Higher On Monday
↗
June 17, 2024
Via
Benzinga
Cytokinetics Reveals More From The Study That Boosted Shares 83% In A Day
↗
May 13, 2024
The company is hoping to take on Bristol Myers Squibb's Camzyos, a treatment for obstructive HCM.
Via
Investor's Business Daily
LXRX Stock Earnings: Lexicon Pharmaceuticals Meets EPS, Misses Revenue for Q1 2024
↗
May 02, 2024
LXRX stock results show that Lexicon Pharmaceuticals met analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Via
InvestorPlace
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
